Detalhe da pesquisa
1.
The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer.
Mol Cancer
; 22(1): 185, 2023 11 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-37980528
2.
Tertiary lymphoid structure and neutrophil-lymphocyte ratio coordinately predict outcome of pembrolizumab.
Cancer Sci
; 114(12): 4622-4631, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37752769
3.
Sex as a biological variable: Mechanistic insights and clinical relevance in solid organ transplantation.
Am J Transplant
; 23(11): 1661-1672, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37543092
4.
Pattern of expression of microRNA in patients with radiation induced bladder injury.
Oncology
; 2023 Dec 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38160665
5.
Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on NLR Fluctuation and Liver Metastases.
Oncology
; 2023 Oct 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37839399
6.
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
BJU Int
; 131(4): 477-485, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36098556
7.
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma.
World J Urol
; 41(12): 3585-3591, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37924336
8.
Importance of Management of Lifestyle-Related Diseases After Kidney Donation to Living Donors.
Transplant Proc
; 56(3): 479-481, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38326206
9.
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study.
Clin Genitourin Cancer
; 22(1): 76-83, 2024 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37880020
10.
Usefulness of Dietary Salt Restriction in Kidney Transplant Recipients: Analysis of Blood Pressure Levels Depending on the Differences in the Levels of Salt Intake.
Transplant Proc
; 55(4): 841-844, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37169600
11.
Tissue Distribution of Cisplatin by Intra-arterial Infusion Route in Comparison to Systemic Route: Implication to Therapy for Node-positive Bladder Cancer.
In Vivo
; 37(1): 143-148, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36593015
12.
Optimal Time Point for Evaluation of Response to Pembrolizumab Treatment in Japanese Patients With Metastatic Urothelial Carcinoma.
Cancer Diagn Progn
; 3(3): 370-376, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37168961
13.
Concurrent palliative radiation with pembrolizumab for platinum-refractory urothelial carcinoma is associated with improved overall survival.
Clin Transl Radiat Oncol
; 39: 100558, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36545361
14.
Real-world survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for nonmetastatic castration-resistant prostate cancer.
Cancer Med
; 12(19): 19414-19422, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37706578
15.
Prognostic value of the fluctuation in the neutrophil-lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma.
Urol Oncol
; 40(7): 344.e11-344.e17, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35346572
16.
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab.
Cancers (Basel)
; 14(22)2022 Nov 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36428750
17.
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer.
J Immunother Cancer
; 10(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35039462
18.
Risk Classification for Overall Survival by the Neutrophil-Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab-A Multicenter Collaborative Study in Japan.
Cancers (Basel)
; 13(14)2021 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34298768
19.
Early Prostate-Specific Antigen (PSA) Change at Four Weeks of the First-Line Treatment Using Abiraterone and Enzalutamide Could Predict Early/Primary Resistance in Metastatic Castration-Resistant Prostate Cancer.
Cancers (Basel)
; 13(3)2021 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33573172